Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Horwitz

Showing results (141-150 of 209) with videos related to

Pageof 21
Sort By:
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
American Journal of Hematology|January 30, 2026
CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSilvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Haematologica|May 16, 2024
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosisWilliam T Johnson, Zachary D Epstein-Peterson, Nivetha Ganesan, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Pageof 21

Showing results (141-150 of 209) with videos related to

Sort By:
Pageof 21
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
American Journal of Hematology|January 30, 2026
CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSilvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Haematologica|May 16, 2024
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosisWilliam T Johnson, Zachary D Epstein-Peterson, Nivetha Ganesan, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Pageof 21